Being SunSmart: At a glance
Why be SunSmart? Skin cancer is the most common type of cancer in Ireland. Yet, in most cases, it is also one of the most preventable forms of cancer. You can reduce your risk by avoiding overexposure to ultraviolet radiation (UV) from sunlight or artificial sources e.g. sunbeds. Reduce your risk, protect your skin: Be […]
SunSmart video series encourages everyone to enjoy the sun safely
ISF, NCCP, ULHG and Healthy Ireland SunSmart launch video series to increase awareness and adoption of skin cancer preventative behaviours to help reduce the risk of skin cancer, the most common cancer in Ireland The ISF and Dr Sinead Field, Consultant Dermatologist at University Hospital Limerick, in association with HSE’s National Cancer Control Programme (NCCP), […]
Watch our webinar ‘Understanding Hidradenitis Suppurativa (HS)’
Did you miss our webinar on, Understanding Hidradenitis Suppurativa (HS)? No problem, watch it below. In this SkinSideOut webinar, on HS Awareness Week 2021, Consultant Dermatologist, Prof Brian Kirby spoke about current treatments for HS and what’s coming down the line and long-time HS patient advocates, Barry McGrath and Suzanne Moloney about their journey to […]
RTÉ Interview on Living with Psoriasis
In the recording below, Irish broadcaster Zoe Ryan, who has lived with psoriasis since childhood, speaks with Oliver Callan about her journey to diagnosis and the effect psoriasis can have on mental health, quality of life and overall wellbeing. For more information about psoriasis, visit our Psoriasis Section to download our booklet, What you need to […]
Self-Care Tips for Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) Awareness Week takes place the June 3-9, this year. The following general measures can be very helpful in the management of Hidradenitis Suppurativa (HS). 1: Stop smoking Research has shown that people with Hidradenitis Suppurativa (HS) are far more likely to be smokers. Smoking is thought to worsen HS and stopping smoking […]
SECURE-AD Update: How do COVID-19 vaccinations affect patients with eczema?
The SECURE-AD patient survey is adapting to include the question, ‘How does the COVID-19 vaccination affect patients with eczema?’ In 2020, the SECURE-AD Patient survey was launched to understand how COVID-19 infections impacted on patients with eczema. The results will be available shortly as the research team are preparing their first scientific publication. Preliminary results […]
Watch our webinar on ‘The Future of Atopic Eczema Care in Ireland’
Did you miss our webinar on, The Future of Atopic Eczema Care in Ireland? No problem, watch it below. In this SkinSideOut webinar, our panel, eczema patient advocate, Paul Herriott; Consultant Dermatologist, Prof Alan Irvine; and Advanced Nurse Practitioner in Dermatology and ISF Clinical Helpline Manager, Carmel Blake talk about recent medical advancements in the […]
Webinar: The Future of Atopic Eczema Care in Ireland
This event has ended. In this SkinSideOut webinar, we take a look at The Future of Atopic Eczema Care in Ireland. You’ll hear about recent medical advancements in the treatment of eczema and what this will mean for the future; how COVID-19 has impacted dermatology services and how they have adapted to deliver care; and […]
Survey: New Phase of First Patient-Led Impact Research Study in Dermatology
The GRIDD project is the first global patient-initiated and patient-led impact research study in dermatology. Global Research on the Impact of Dermatological Diseases (GRIDD) was launched in 2017 by the International Alliance of Dermatology Patient Organizations (GlobalSkin). The ISF, a proud member of GlobalSkin, are calling on any adult affected by a skin condition to […]
Update on Dupilumab: HSE Management Supports Reimbursement
Less than a month from the last major development, Dupilumab receives green light for funding In a statement to the ISF and healthcare professionals this afternoon, the HSE notified patients that the Executive Management Team has supported reimbursement of Dupilumab under High Tech (Drugs Scheme) Arrangements. Availability of the new ‘first-in-class’ treatment will be “subject to […]
